Financials data is unavailable for this security.
View more
Year on year Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 's revenues fell -17.50% from 1.03bn to 850.73m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 138.00m to 108.63m, a -21.28% decrease.
| Gross margin | 90.24% |
|---|---|
| Net profit margin | 15.15% |
| Operating margin | 13.98% |
| Return on assets | 3.76% |
|---|---|
| Return on equity | 4.49% |
| Return on investment | 4.43% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd fell by 93.41m. However, the company earned 71.02m from its operations for a Cash Flow Margin of 8.35%. In addition the company used 45.38m on investing activities and also paid 118.98m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.27 |
|---|---|
| Tangible book value per share | 2.20 |
More ▼
Balance sheet in CNYView more
| Current ratio | 6.23 |
|---|---|
| Quick ratio | 6.06 |
| Total debt/total equity | 0.0048 |
|---|---|
| Total debt/total capital | 0.0048 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -21.51%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 88.68% |
| EPS growth(5 years) | -2.87 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -46.68 |
More ▼
